Oppenheimer on BridgeBio Oncology Therapeutics, In (BBOT): 'We think the lack of idiosyncratic toxicity is particularly notable for BBO-10203'

Oppenheimer analyst Matt Biegler reiterated an Outperform rating and $22.00 price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT).

The analyst comments "BBOT unveiled updated data this morning across is oncology programs. We think BBO-8520 continues to look like the best KRASG12C inhibitor in development, with the advantages of its ON/OFF binding mechanism now showing up clinically (i.e., lower exposures that enable broader target coverage without the toxicity of OFF-only binders). With additional patients, monotherapy ORR is now 65%. Early pembro combination data suggest '8520 can be dosed at fully active levels, avoiding dose reductions and hepatotoxicity seen with other G12Cs. Updates from BBO-11818 and BBO-10203 were earlier but clean, with no unexpected safety signals. We think the lack of idiosyncratic toxicity is particularly notable for BBO-10203 given its novel RAS-PI3Kα dimer-breaker mechanism, reinforcing confidence in BBOT's broader combination strategy heading into 2026. Reiterate Outperform; $22 PT."

For an analyst ratings summary and ratings history on BridgeBio Oncology Therapeutics, In click here. For more ratings news on BridgeBio Oncology Therapeutics, In click here.

Shares of BridgeBio Oncology Therapeutics, In closed at $11.59 yesterday.

You May Also Be Interested In

• Berenberg Upgrades Accelleron Industries AG (ACLN:SW) to Buy
• JPMorgan Downgrades PLDT Inc. (TEL:PM) (PHI) to Neutral
• Jefferies Downgrades Aegis Vopak Terminals (AEGISVOP:IN) to Hold